Prucalopride in Patients With Chronic Idiopathic Constipation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00575614|
Recruitment Status : Completed
First Posted : December 18, 2007
Last Update Posted : May 29, 2008
The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic idiopathic constipation.
Prucalopride given at a dose of 1 mg o.d. for 4 weeks to female patients with chronic constipation shows a favourable effect on most of the efficacy parameters assessed in this trial. This dosage can be considered safe and generally well-tolerated.
|Condition or disease||Intervention/treatment||Phase|
|Constipation||Drug: prucalopride Drug: placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||87 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Study to Evaluate the Effect of a 1 mg o.d. Dose of Prucalopride in Patients With Chronic Idiopathic Constipation|
|Study Start Date :||April 1997|
|Actual Primary Completion Date :||March 1999|
|Actual Study Completion Date :||March 1999|
|Active Comparator: 1||
1 mg o.d.
Other Name: Resolor
|Placebo Comparator: 2||
- Whole gut transit [ Time Frame: 4 weeks ]
- Ano-rectal physiology [ Time Frame: 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00575614
|Principal Investigator:||Michael Kamm, MD||Northwick Park Hospital|